The global orphan drugs market is estimated to have reached a value of $86.3 billion during 2011. Between 2005 and 2011 the CAGR growth in the global orphan drugs market reached 9.6%. It is forecasts, however, that the market will witness near flat sales growth between 2011 and 2017. The oncology sector of orphan drugs will continue to be the largest market, accounting for around 42% of orphan drug sales during 2011. This sector is expected to reach around $5.3 billion worth of sales between 2011 and 2017.
Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, with orphan drugs seen as a great opportunity for this. Our report provides analysis of this sector and includes brands that have gained orphan drug approval from the FDA, as well as Phase III pipeline candidates that have gained orphan drug designation from the FDA.
For more information on the global orphan drugs market, please click here: Global Orphan Drugs Market
For more information on the Healthcare and Medical market, please click here: Healthcare and Medical Market
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.